Insider Selling: Twist Bioscience Corp (NASDAQ:TWST) CTO Sells 19,553 Shares of Stock

Share on StockTwits

Twist Bioscience Corp (NASDAQ:TWST) CTO Bill Peck sold 19,553 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $30.06, for a total value of $587,763.18.

Bill Peck also recently made the following trade(s):

  • On Tuesday, October 1st, Bill Peck sold 20,000 shares of Twist Bioscience stock. The shares were sold at an average price of $23.13, for a total value of $462,600.00.
  • On Tuesday, September 3rd, Bill Peck sold 20,447 shares of Twist Bioscience stock. The stock was sold at an average price of $28.43, for a total value of $581,308.21.

Shares of NASDAQ:TWST traded up $0.34 during midday trading on Friday, hitting $22.66. The company had a trading volume of 280,262 shares, compared to its average volume of 268,530. The business’s 50-day simple moving average is $26.67 and its 200-day simple moving average is $27.27. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.18 and a quick ratio of 6.96. The stock has a market cap of $737.81 million and a price-to-earnings ratio of -0.89. Twist Bioscience Corp has a twelve month low of $12.38 and a twelve month high of $35.95.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Thursday, August 1st. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The business had revenue of $13.60 million for the quarter, compared to analyst estimates of $12.51 million. Twist Bioscience had a negative return on equity of 168.45% and a negative net margin of 204.63%. As a group, sell-side analysts forecast that Twist Bioscience Corp will post -3.8 EPS for the current year.

A number of equities analysts have issued reports on the company. Zacks Investment Research downgraded Twist Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, October 5th. ValuEngine downgraded Twist Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $26.55.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC acquired a new stake in shares of Twist Bioscience in the second quarter valued at $3,216,000. Susquehanna International Group LLP purchased a new position in Twist Bioscience in the second quarter valued at $404,000. Nuveen Asset Management LLC purchased a new position in Twist Bioscience in the second quarter valued at $2,527,000. Morgan Stanley boosted its holdings in Twist Bioscience by 28.9% in the second quarter. Morgan Stanley now owns 2,223 shares of the company’s stock valued at $65,000 after purchasing an additional 499 shares during the period. Finally, Invesco Ltd. purchased a new position in Twist Bioscience in the second quarter valued at $2,264,000. 42.69% of the stock is owned by institutional investors and hedge funds.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Read More: How to execute a trade ex-dividend strategy?

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.